Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
168.25
+0.37 (0.22%)
At close: Aug 29, 2025, 4:00 PM
168.25
0.00 (0.00%)
After-hours: Aug 29, 2025, 4:15 PM EDT
Natera Employees
Natera had 4,434 employees as of December 31, 2024. The number of employees increased by 1,141 or 34.65% compared to the previous year.
Employees
4,434
Change (1Y)
1,141
Growth (1Y)
34.65%
Revenue / Employee
$442,997
Profits / Employee
-$57,113
Market Cap
23.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
Dec 31, 2023 | 3,293 | 275 | 9.11% |
Dec 31, 2022 | 3,018 | 348 | 13.03% |
Dec 31, 2021 | 2,670 | 855 | 47.11% |
Dec 31, 2020 | 1,815 | 776 | 74.69% |
Dec 31, 2019 | 1,039 | 64 | 6.56% |
Dec 31, 2018 | 975 | 82 | 9.18% |
Dec 31, 2017 | 893 | 41 | 4.81% |
Dec 31, 2016 | 852 | 136 | 18.99% |
Dec 31, 2015 | 716 | 42 | 6.23% |
Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTRA News
- 8 hours ago - Natera Provides Update on Patent Litigation with NeoGenomics - Business Wire
- 1 day ago - Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer - Business Wire
- 4 days ago - Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer - Business Wire
- 7 days ago - Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine - Business Wire
- 7 days ago - Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Business Wire
- 11 days ago - IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit - Business Wire
- 21 days ago - Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
- 21 days ago - Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript - Seeking Alpha